Adjuvant therapy for pancreatic cancer to treat or not to treat?

ONCOLOGY

Volumn 21, Issue 6, 2007, Pages 712-718

  Keedy, Vicki L ^a,b   Berlin, Jordan D ^a  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b 777 Preston Research Bldg ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN;

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PANCREAS CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; STANDARD; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUOROURACIL; HUMANS; META-ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 34249936837     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Kim J, Czischke K, Brennan M, et al: Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg 6:763-769, 2002.
2. Kalser M, Ellenberg S: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-904, 1985.
3. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Ann Surg 230:776-784, 1999.
4. Neoptolemos JP, Kerr DJ, Beger H: ESPAC-1 trial progress report: The European randomized adjuvant study comparing radiochemotherapy, 6 months chemotherapy and combination therapy versus observation in pancreatic cancer. Digestion 58:570-577, 1997.
5. Neoptolemos JP, Dunn JA, Stocken DD, et al: Adjuvant chemoradiotherapy in resectable pancreatic cancer: A randomized controlled trial. Lancet 358:1576-1585, 2001.
6. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004.
7. Abrams RA, Lillemoe KD, Plantadosi S: Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet 358:1565-1566, 2001.
8. Stocken DD, Buchler MW, Dervenis C, etal: Meta-analysis of randomised adjuvant trials for pancreatic cancer. Br J Cancer 92:1372-1381, 2005.
9. Regine WF, Winter KW, Abrams R, et al: RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma (abstract 4007). J Clin Oncol 24(18S):180s, 2006.
10. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 297:267-277, 2007.
11. Bakkevold KE, Arnesjo B, Dahl O, et al: Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas, and papilla of Vater - results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A:698-703, 1993.
12. Picozzi VJ, Kozarek RA, Traverso LW: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 285:476-480, 2003.
13. Tan BR, Strasberg S, Myerson R, et al: Adjuvant interferon- and gemcitabine-based chemoradiation for patients with resected pancreatic adenocarcinoma (abstract 177). 2007 Gastrointestinal Cancers Symposium; Orlando, Fla; January 19-21, 2007.
14. Stathopoulos GP, Syrigos K, Aravantinos G, et al: A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 95:587-592, 2006.
15. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005.
16. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG] (abstract 1). J Clin Oncol 23(16S):1s, 2005.
17. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial. J Clin Oncol 22:2610-2616, 2004.
18. Kindler HL, Friberg G, Singh DA, et al: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033-8040, 2005.
19. Kindler HL, Niedzwiecki D, Hollis D, et al: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303 (abstract 108). 2007 Gastrointestinal Cancers Symposium; Orlando, Fla; January 19-21, 2007.
20. Yeo C, Cameron J, Sohn T, et al: Six hundred fifty consecutive pancreatic-oduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 226:248-257, 1997.
21. Willett C, Lewandrowski K, Warshaw A, et al: Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 217:144-148, 1993.
22. Moutardier V, Turrini O, Huiart L, et al: A reappraisal of preoperative chemoradiation for localized pancreatic head ductal adenocarcinoma in a 5-year single-institution experience. J Gastrointest Surg 8:502-510, 2004.
23. Sasson, AR, Wetherington, RW, Joffman JP, et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Analysis of histopathology and outcome. Int J Gastrointest Cancer 34:121-128, 2003.
24. Nakamori S, Nakahira S, Miyamoto A, et al: Long-term outcomes of preoperative chemoradiation therapy with gemcitabine and accelerated hyperfractionated radiation of resectable pancreatic cancer (abstract 14004). J Clin Oncol 24(18S):624s, 2006.
25. Pipas J, Barth R, Zaki B, et al: Docetaxel/ gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 12:995-1004, 2005.
26. Ammori J, Colletti L, Zalupski M, et al: Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 7:766-772, 2003.
27. Kastl S, Brunner T, Hermann O, et al: Neoadjuvant radio-chemotherapy in advanced primarily non-resectable carcinomas of the pancreas. Eur J Surg Oncol 26:578-582, 2000.